Identification of cellular targets in human intrahepatic cholangiocarcinoma using laser microdissection and accurate mass and time tag proteomics.: Novel cellular targets in human intrahepatic cholangiocarcinoma by Dos Santos, Alexandre et al.
Identification of cellular targets in human intrahepatic
cholangiocarcinoma using laser microdissection and
accurate mass and time tag proteomics.
Alexandre Dos Santos, Magali Court, Vale´rie Thiers, Sokhavuth Sar,
Catherine Guettier, Didier Samuel, Christian Bre´chot, Je´roˆme Garin, France
Demaugre, Christophe Masselon
To cite this version:
Alexandre Dos Santos, Magali Court, Vale´rie Thiers, Sokhavuth Sar, Catherine Guettier, et
al.. Identification of cellular targets in human intrahepatic cholangiocarcinoma using laser
microdissection and accurate mass and time tag proteomics.: Novel cellular targets in human
intrahepatic cholangiocarcinoma. Molecular and Cellular Proteomics, American Society for
Biochemistry and Molecular Biology, 2010, 9 (9), pp.1991-2004. <10.1074/mcp.M110.000026>.
<inserm-00515623>
HAL Id: inserm-00515623
http://www.hal.inserm.fr/inserm-00515623
Submitted on 31 May 2011
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

Novel cellular targets in human intrahepatic cholangiocarcinoma 
1 
Identification of cellular targets in human intrahepatic 
cholangiocarcinoma using laser microdissection 
 and AMT-tag proteomics. 
Alexandre Dos Santos1,2, Magali Court3,4,5, Valérie Thiers1,2,6, Sokhavuth Sar1,2, Catherine 
Guettier1,2,7, Didier Samuel1,2, Christian Bréchot1,2,8, Jérôme Garin3,4,5, France Demaugre1,2, 
Christophe D. Masselon3,4,5,* 
 
1
 INSERM, Unité 785, Villejuif, F-94800, France 
2
 Univ Paris-Sud, UMR-S 785, Villejuif, F-94800, France 
3
 CEA, DSV, iRTSV, Laboratoire d’Etude de la Dynamique des Protéomes, Grenoble, F-38054, France 
4
 INSERM, Unité 880, Grenoble, F-38054, France 
5
 Université Joseph Fourier, Grenoble, F-38054, France 
6  Institut Pasteur, Département de Virologie, Paris, F-75015, France 
7 AP-HP Hôpital Bicêtre, Service d’Anatomie Pathologique, Le Kremlin-Bicêtre, F-94270, France 
8
 Merieux Alliance, Lyon, F-69000, France 
 
 
 
 
- Keywords: cancer, intrahepatic cholangiocarcinoma, laser microdissection, AMT proteomics, 
biomarkers 
- Running title: Novel cellular targets in human intrahepatic cholangiocarcinoma 
- Abbreviations: AMT, Accurate Mass and Time; CCA, Cholangiocarcinoma; EMT, Epithelial to 
Mesenchymal Transition; HCC, Hepatocellular Carcinoma; ICC, Intrahepatic 
Cholangiocarcinoma; LM, Laser Microdissection; TMA, Tissue Micro-Array. 
 
                                                 
*
  to whom correspondence should be addressed (email: christophe.masselon@cea.fr) 
Novel cellular targets in human intrahepatic cholangiocarcinoma 
2 
Abstract  
Obtaining accurate protein profiles from homogeneous cell populations in heterogeneous tissues 
can enhance the capability to discover protein biomarkers. In this context methodologies to access 
specific cellular population and analyze their proteome with exquisite sensitivity have to be 
selected. We report here the results of an investigation using a combination of laser microdissection 
and accurate mass and time tag proteomics. The study was aimed at the precise determination of 
proteome alterations in intrahepatic cholangiocarcinoma, a markedly heterogeneous tumor. This 
cancer, which is difficult to diagnose and carries a very poor prognostic, has shown an unexplained 
increase in incidence over the last few years. Among a pool of 574 identified proteins, we were able 
to report on altered abundance patterns affecting 39 proteins conforming to a variety of potential 
tumorigenic pathways. The reliability of the proteomics results was confirmed by Western blot and 
immunohistochemistry on matched samples. Most of the proteins displaying perturbed abundances 
had not yet been described in the setting of intrahepatic cholangiocarcinoma. These include proteins 
involved in cell mobility and actin cytoskeleton remodeling, which may participate in the epithelial 
to mesenchymal transition, a process invoked in migration and invasion of cancer cells. The 
biological relevance of these findings was explored using a tissue microarray. An increased 
abundance of vimentin was thus detected in 70% of intrahepatic cholangiocarcinoma and none of 
the controls. These results suggest that vimentin could play a role in the aggressiveness of ICC and 
provide a basis for the serious outcome of this cancer. 
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Introduction 
Cholangiocarcinoma (CCA), which arises from the hepatic bile ducts, is the primary cancer 
accounting for ~10-15% of all hepatobiliary malignancies. CCA is categorized by the International 
Classification of Diseases for Oncology into intrahepatic and extrahepatic forms, the latter including 
perihilar, hilar and distal bile duct CCA. Global incidence rate of intrahepatic cholangiocarcinoma 
(ICC) has increased by 2-6% during recent decades, while annual incidence rate of the more 
common, extrahepatic form has remained relatively stable (1, 2). The diagnosis of ICC remains 
particularly challenging since the disease can mimic metastasis to the liver or hepatocellular 
carcinoma (HCC). The only potentially curative treatment options available at present are surgical. 
Unfortunately, the majority of patients are diagnosed at an advanced, unresectable stage because of 
the initially silent clinical characteristics of this malignancy. The prognosis of ICC is therefore 
devastating, with survival of less than 24 months following diagnosis. Although several risk factors 
have been reported as contributing to the development of the disease, most cases of ICC occur in 
the absence of known etiological factors (3-5). As a consequence, considerable efforts have been 
made to identify reliable markers to enable the early detection of biliary cancers and provide new 
insights into the pathogenesis of this deadly disease (6). Recent studies have focused on the 
cytokines and growth factors (7, 8) produced by CCA cells, as well as on the proteomic analysis of 
serum and bile (9, 10). Follow-up studies are ongoing to determine the sensitivity and specificity of 
the markers that have emerged from these investigations. 
Tumor tissue is undeniably the most appropriate resource to investigate tumor-specific signals. 
Indeed, the determination of alterations to the protein profiles of ICC may offer opportunities to 
identify tumor-specific markers. To date, proteomics studies performed using tumor tissues have 
mainly tried to identify proteins with a differential expression between HCC and ICC in order to 
prevent the misclassification of these pathologies (11, 12). Furthermore, these studies, performed on 
total liver homogenates, were not appropriate to detect proteins with altered expression in tumorous 
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cholangiocytes. Indeed, ICC tumor cells are essentially embedded in an abundant stroma containing 
inflammatory cells and fibroblasts, which may impair the detection of proteins displaying tumor-
specific expression patterns (13). In summary, because no proteomics studies have so far been 
performed on isolated cholangiocytes, any proteome alterations in the setting of ICC remain a 
matter of speculation. 
Laser microdissection (LM) has emerged as a suitable tool to selectively extract cells of interest 
from their natural environment. This technology has been employed extensively to profile global 
gene expression in purified tumor cells (14-16). It has also been used successfully in experiments 
designed to discover protein biomarkers through mass spectrometry-based proteomics studies (17-
19). However, working with such small samples challenges conventional proteomics techniques in 
terms of sensitivity and the precision of quantitation. 
One particularly efficient method for proteome analysis is the so-called Accurate Mass and Time 
(AMT) tag approach, where high performance liquid chromatography (HPLC) and high resolution 
Fourier transform ion cyclotron resonance mass spectrometry (FTICR-MS or FTMS) work in 
synergy to achieve a broad proteome coverage, even for small sample amounts (20, 21). A recent 
report demonstrated the significant advantage of the AMT tag method over more conventional 
proteomics technologies in enabling significantly broader proteome coverage using the minute 
protein quantities available from tissue microdissection (22). 
In the present study, we used an AMT tag strategy to determine the differential protein profile 
between tumorous and non tumorous microdissected cholangiocytes, in order to define specific 
proteome alterations of human ICC. Among proteins with altered expression in ICC, we detected a 
panel of proteins conforming to potential tumorigenic pathways which could be candidates as 
therapeutic targets and tumor markers for this lethal disease. 
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Experimental Procedures 
- Patients and tissue samples 
Liver specimens were obtained from the “Centre de Ressources Biologiques Paris-Sud”, Paris-Sud 
University, France. Access to this material was in agreement with French legislation. Tissue 
samples were collected at the time of surgical resection with the prior informed consent of patients. 
The local research ethics committee specifically approved this procedure. Detailed clinical data 
regarding these subjects are summarized in Table 1. Tumorous and adjacent non-tumorous hepatic 
tissues from four patients with intrahepatic cholangiocarcinoma and five perihilar samples 
containing large bile duct sections from control subjects without ICC, were obtained within 30 
minutes of surgical resection. These samples were immediately frozen in liquid nitrogen and stored 
at –80°C until use. The tumors were graded by a pathologist by means of microscopic examination. 
- Laser microdissection (LM)  
The liver sections were prepared and treated as previously described (23). LM was performed using 
a PALM Microbeam system (Carl Zeiss Inc.) (see Supplementary Figure 1). From each liver 
sample, approximately 100,000 cells corresponding to 10 mm2 were microdissected and catapulted 
directly into the cap of a microcentrifuge tube containing 10µl 10% SDS. Cell lysates were stored at 
-80°C until use. Based on a careful review, each section was estimated to contain ≥90% of the 
desired cells. 
-Mass spectrometry analysis 
1- Sample preparation  
For AMT tag database generation, LC-MS/MS analyses have to be performed on fractionated 
samples to achieve decent proteome coverage. For this purpose, four to six samples were pooled per 
pair of patients with or without ICC (Figure 1A). Thirty microliters of lysis buffer (50mM Tris pH 
6.8, 2% SDS, 0.35M beta-Mercaptoethanol and 4M urea) were added to each pool and the samples 
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were deposited on a 1D-SDS-PAGE gel before being subjected to a short separation (pseudo-
stacking) in order to prevent the sample from being distributed over the whole gel lane. After 
Coomassie Blue staining to reveal proteins, each pseudo-stacking band was cut into 8 slices and the 
corresponding fractions were digested in-gel with trypsin (Promega, Charbonnières-les-bains, 
France), as described previously (24). An estimated 0.8 to 1.2 µg of total protein was injected for 
each gel fraction. All fractions were analyzed with LC-MS/MS in triplicate and the resulting 
peptide identifications were used to compile an AMT tag database. 
For quantitative studies, protein extracts from individual patient biopsies were deposited on 1D-
SDS-PAGE gel and migrated in the stacking mode (Figure 1B). The stacked gel band associated 
with each patient was then excised and digested in-gel as described above. The resulting peptide 
mixtures were analyzed in triplicate using LC-FTMS. Peptides from approximately 20,000 cells 
were injected for each LC-FTMS analysis. 
2- nano-HPLC-MS and MS/MS analysis 
All proteomic analyses were performed using the 7-tesla hybrid linear ion trap Fourier transform 
ion cyclotron resonance mass spectrometer LTQ-FT Ultra (Thermo Electron, Bremen, Germany) 
coupled to an Ultimate 3000 (LC-Packings, Amsterdam, Netherlands) nano HPLC system mounted 
with an LC-Packings Pepmap nano-column (75 µm ID, 15 cm long, 3 µm particles, 100 Ǻ pores). 
The chromatographic separation conditions were as described previously (25). 
2.1- AMT tag database generation (MS/MS mode) 
The FTMS detector was used for the survey scan within the m/z range of 400-1850 at a resolution 
setting of 50,000 (25). MS/MS was performed in the linear ion trap in parallel with high resolution 
acquisition of the MS signal on the FT detector. Dynamic exclusion prevented the acquisition of 
multiple MS/MS spectra for a given precursor ion (mass tolerance = ± 2 ppm, repeat MS/MS 
acquisition = 2x within 30 s, exclusion duration = 180 s, exclusion list size = 500 entries.) 
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MS/MS data were processed using Mascot Distiller (Matrix Science, UK)  to produce peak lists 
(e.g. .mgf files) that were subsequently submitted to the Mascot v.2.2.03 (Matrix Science, UK) 
search engine for database searches against the SwissProt-TREMBL database (compiled from 
SwissProt release v54.8 and TREMBL release v37.8) using the taxonomy “Homo sapiens (human)” 
(72,036 protein sequences). Mascot search parameters are listed in supplementary Table 1. A target-
decoy database search was performed as described previously (26) in order to estimate false 
positive rates. Identifications were validated automatically (Filters: Rank=1 + score>identity 
threshold at p-value<0.05) and compiled in an MS identification database using the IRMa home-
made software (27). The MS identification database was then converted into an AMT tag database 
(Microsoft Access format) by grouping the multiple occurrences of each identified peptide. To 
reduce false positives, we opted for the removal of peptides with length ≤6 amino acids. In addition, 
only proteins covered by at least two peptides were considered for inclusion in the database, with 
the exception of proteins covered by a single peptide (length >6) with a Mascot score greater than 
or equal to 50. Peptides spectrum matches for these peptides have been compiled and are provided 
as supplementary figure 2. 
2.2- Quantitative MS acquisitions (MS mode) 
All quantitative MS data were obtained under the FTMS detection mode on an m/z range of 400-
1850 and resolution of 50,000. We took advantage of the parallel acquisition capability of the LTQ-
FT instrument to acquire a single MS/MS spectrum during each survey scan. This allowed us to 
further populate the AMT tag database without compromising the MS data acquisition rate.  
MS data were processed using the Decon-2LS/VIPER open-source software suite provided by 
PNNL (see http://ncrr.pnl.gov/). Individual MS spectra were de-isotoped using Decon-2LS. The 
VIPER software then ensured LC-MS feature detection, retention time alignment and feature 
identification in the AMT tag database, as previously described (28) We opted to further filter the 
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list of identifications by keeping only matches with a confidence score (i.e. SLIC score)(29) higher 
than 0.9.  
2.3- Statistical analysis 
In order to extract lists of peptides that were differentially abundant in the two cholangiocytes 
populations, we applied a statistical analysis to the data based on the Spectral Index (SpI) approach 
proposed by Heineke and coworkers (30). The SpI method was developed in the context of label-
free quantification using spectral counting techniques (31).  It was necessary to adapt it slightly to 
fit the needs of our AMT-based label-free strategy which is reliant on peptide signal extraction. To 
achieve this, we replaced protein spectral counts by individual peptide abundances, and instead of 
defining the SpI for each identified protein, we defined an Abundance Index (AbI) for each 
identified peptide. The AbI was thus defined as: 
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Where A  (resp. B ) was the average abundance of a peptide in the population A (resp. B); DAN and 
D
BN the numbers of patients in each population where the peptide was detected; and TAN and TBN the 
total numbers of samples in each population. The distribution of observed AbI for all the detected 
peptides was then compared to the AbI distribution obtained by random permutation of the datasets 
across the two populations in order to estimate the variance. Permutations thus allowed the 
establishment of a confidence interval to assess differential abundances. It is worth mentioning here 
that, although the AbI method was designed to handle missing values, it is only applicable to 
peptides which have been detected at least once in each population. All calculations were performed 
using JMP v.7.0.1 software (SAS institute Inc.). 
3- Immunochemical analysis 
3.1- Western blot analysis. 
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For Western blot analysis, samples from the batches of microdissected cholangiocytes were run on 
SDS-PAGE and transferred onto nitrocellulose membranes as previously described (23). The 
membranes were then blocked with PBS/ 5% skimmed milk / 0.1% Tween 20 for two hours at 
room temperature before being incubated overnight with appropriate dilutions of antibodies raised 
against Vimentin (DAKO, V9 clone), carbonic anhydrase II (Santa Cruz Biotechnology) and 
profilin-1 (Cell Signaling Technology). The primary antibody was detected using appropriate 
horseradish peroxidase-coupled secondary antibodies and the ECL plus kit (GE Healthcare) for 
signal visualization.  
3.2- Construction of tissue microarray  
The hepatic tumors selected for inclusion in a tissue microarray (TMA) comprised 23 ICC, 17 hilar 
cholangiocarcinoma, 19 HCC and 22 non-tumorous liver samples (see supplementary Table 2). All 
cases were reviewed by a pathologist. Intrahepatic cholangiocarcinoma cases were categorized as 
trabeculo-tubular (19 cases) or invasive papillary (4 cases) carcinomas. Before arraying, sections 
from each tissue block were stained with hematoxylin and eosin in order to define morphologically 
representative areas of the tumor. Three tissue cylinders with a diameter of 1 mm were then 
punched from carefully selected, morphologically representative regions of each donor tissue block 
and deposited in a recipient block using a tissue-arrayer (MTAI Beecher Instruments). Four 
micrometer thick sections of this array block were stained with hematoxylin and eosin to enable 
histological verification of the adequacy of the arrayed tumor tissues.  
3.3- Immunohistochemical analysis  
Immunohistochemical analysis was performed using formalin-fixed and paraffin-embedded tissue 
specimens that were matched with the samples used for LM. Deparaffinized 4-micrometer thick 
sections were treated with primary antibodies against vimentin and carbonic anhydrase II overnight 
at 4°C after appropriate antigen retrieval treatment. Primary antibody/antigen binding was detected 
using the Vectastain ABC system (Vector Laboratories). Nuclei were counterstained with 
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hematoxylin. Labeling specificity was determined by omitting the primary antibody during the 
experiment. Using the same procedure, labeling of microarrayed tissue sections by the anti-vimentin 
antibody was carefully analyzed by a pathologist, and was considered to be negative when fewer 
than 5% of the cells of interest were immunostained. Statistical significance was calculated using a 
two-tailed Fisher’s exact test under StatEl software (www.adscience.eu), with p< 0.01 for statistical 
significance. 
Results 
A major feature of ICC is the presence of an important stromal reaction in the tumor. Thus in order 
to obtain protein abundance profiles that were relevant to ICC tumor cells, we opted for the laser 
microdissection technique so as to collect enriched populations of cholangiocytes (see 
supplementary Figure 1). ICC tumor cells were isolated from the livers of four patients. Biliary cells 
dissected from large bile ducts present in the perihilar sections of the livers of five patients without 
ICC or any biliary tract pathology were used as controls. 
Proteomics study using an AMT tag strategy 
Generation of an AMT tag database 
The first step in the AMT tag methodology consists in generating a database of peptides that can be 
identified in the sample under study.  To achieve this, we analyzed peptide mixtures resulting from 
digestion of the various fractions obtained from pools of microdissected cells separated on 1D gels 
(see Figure 1A). Following LC-MS/MS analysis and Mascot search, peptide identifications were 
compiled in a so-called AMT tag database. Only proteins identified by at least two peptides were 
considered for inclusion, except when a single peptide had a Mascot score higher than 50. In total, 
21,902 peptide identifications were validated and grouped by sequence, molecular weight and 
average retention time. The median Mascot score for the peptides that passed our filtering criteria 
for inclusion in the AMT database was 50.56, and 90% of the peptides considered scored higher 
than 33.27. The resulting AMT tag database thus contained 2,499 distinct peptides indicative of 
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4,508 protein accessions. When shotgun approaches are used for protein identification, a certain 
degree of redundancy can be observed in the list of proteins identified.  Indeed, several proteins in 
our database, and particularly isoforms or sequence variants, were covered by the same sub-sets of 
peptides. In order to reduce this redundancy in the protein list, proteins characterized by the same 
sub-set of peptides were grouped into so-called protein groups (32). Supplementary Table 3 lists the 
574 protein groups thus identified, and the individual proteins within these groups. This list can be 
considered as the minimal list of proteins required to account for all the peptides identified. In fact, 
the average peptide coverage for the 574 proteins incorporated in the AMT database was of the 
order of five peptides per protein. 
The sub-cellular localization of identified proteins was determined using Ingenuity Pathway 
Analysis software (http://www.ingenuity.com). As shown in supplementary figure 3, while the 
majority (67.4%) of the proteins identified were from the cytoplasm, notable proportions (18.4% 
and 6.5%) arose from the nucleus and plasma membrane respectively. Overall, most sub-cellular 
compartments were represented in the AMT database, suggesting that our approach enabled access 
to a broad cross-section of cellular proteins. 
Label-free quantitative LC-FTMS data evaluation 
After compiling the AMT tag database, we then considered the quantitative data obtained by LC-
FTMS analysis of individual microdissected samples (see Figure 1B). Following data acquisition, 
several tests were performed to assess their quality. This was achieved by evaluating the raw signals 
in all analyses using dedicated software, and by calculating correlations between the peptide 
abundances obtained by different acquisitions. The Chaorder software (33) was used as a first 
means of data evaluation. This algorithm based on a score that measures the similarity between 
pairs of mass spectra enables an assessment of reproducibility and similarity between LC-MS 
experiments. For this purpose, Chaorder computes a pseudo-distance between acquisitions based 
solely on the raw signal. According to Prakash et al. (33), a distance between two points between 0 
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and 0.2 represents levels of reproducibility usually seen in repeat experiments with the exact same 
experimental setup. Figure 2A shows the Chaorder plot obtained by comparing the LC-MS 
acquisitions collected during our experiment. Given the randomized order in which analyses were 
performed, the limited scattering of replicate acquisitions of the same sample was indicative of an 
absence of significant drift in the analytical system. Data consistency was further evaluated using 
pairwise correlations of peptide abundances between acquisitions. The higher the Pearson 
coefficient, the more alike the two datasets were. When plotting the correlation matrix of all 
experiments (see Figure 2B), it became clear that triplicate experiments on the same subject always 
resulted in strongly correlated abundances (R = 0.94 ± 0.04). 
Determination of deregulated proteins  
Before statistical analysis, triplicate acquisitions of the same sample were combined by averaging 
the abundances in all runs for each peptide that had been detected at least in two of the three 
replicates.  This procedure produced four cancer and five control datasets (see supplementary Table 
4). During the quantitative study, we were able to detect and quantify approximately 1850 of the 
2,499 previously sequenced peptides corresponding to 349 proteins identified by at least two 
peptides. 
The nine datasets were subjected to statistical analysis, based on the approach proposed by Heineke 
and coworkers (30). This method combined the relative species abundance and the number of cases 
within a group for which the species was detected into a so-called “Abundance index” (AbI). 
Permutation analysis then enabled the establishment of a confidence interval to assess differential 
abundances. The resulting distributions of AbI obtained for all the detected peptides in the two 
populations are shown in Figure 3. Peptides with AbI values falling outside the 95% confidence 
interval [-0.25 < AbI < 0.53], based on permuted data, were determined to be differentially 
abundant between tumorous and control cholangiocytes (p<0.05). Peptides were then grouped into 
proteins, and only proteins for which at least one proteotypic peptide was detected with differential 
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abundance between the two cholangiocyte populations were retained. This process led to a list of 82 
peptides (associated with 23 proteins) with decreased abundance in tumorous cholangiocytes and 42 
peptides (corresponding to 16 proteins) with higher abundance in these cells (see Table 2). 
With respect to functional considerations, most proteins identified with an altered expression in 
tumorous cells could be grouped in two categories: A first pool of proteins was associated with 
metabolic pathways (glycolysis, neoglucogenesis or fatty acid metabolism), and a second consisted 
of proteins involved in cell structure and/or motility.  
It is worth noting that only peptides detected at least once in each population (ICC and controls) are 
amenable to this type of statistical analysis. As a matter of fact, several peptides were detected only 
in one of the two populations. When assigning these peptides to proteins, it turned out that several 
proteins exclusively covered by population-specific peptides were involved in biological process 
relevant to carcinogenesis (see supplementary Table 5). Among them, the up-regulation of Mac 2 
binding protein (LGALS3BP), a metastasis relative protein C (34), had been reported in various 
cancers including biliary tract carcinoma (35). Likewise, IQGAP2 had shown reduced levels in 
cancers, and the targeted disruption of the murine IQGAP2 gene resulted in the development of 
HCC (36, 37). 
Confirmation of proteomics findings 
Western blot and immunohistochemistry on matched samples. 
In order to verify the reliability of the data obtained during this study, the expression of vimentin, 
profilin1 and carbonic anhydrase II (CAII) was assessed using Western blot in microdissected 
cholangiocytes from the patients and controls included in the proteomic analysis. As determined 
during mass spectrometry analysis (Figure 4A), the expression of vimentin and profilin1 was 
stronger in ICC samples, whereas the immunolabeling of CAII was reduced in these samples when 
compared with the controls (Figure 4B). 
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These results were further corroborated when altered abundance patterns for vimentin and CAII 
were detected in cholangiocytes using immunohistochemistry (Figure 4C). Tissue sections from 
formalin-fixed and paraffin-embedded tissue specimens matched with the samples used for the 
microdissection of cholangiocytes were covered by this analysis. CAII was only detected in biliary 
ducts from control livers and non-tumorous areas of the ICC, whereas anti-CAII antibody did not 
label tumorous cholangiocytes. Conversely, the anti-vimentin antibody labelled vascular smooth 
muscle, Kupffer and inflammatory cells in the analyzed tissue sections. However, vimentin was not 
detected in cholangiocytes lining normal biliary ducts from the control liver or non-tumorous area 
of the cholangiocarcinoma, but was revealed in tumorous intrahepatic cholangiocytes. Similar 
results were obtained with the other tissue specimens (data not shown). Taken together, these data 
established the reliability of our data and the robustness of our strategy regarding the identification 
of proteins displaying altered expression in the setting of ICC. 
Vimentin expression in primary liver cancers. 
In order to further validate the over-abundance of vimentin in ICC, the expression of this protein 
was examined using a tissue microarray comprising samples from a series of patients with primary 
liver cancers including ICC, hilar CCA and HCC. Briefly, we confirmed, in a larger series of liver 
samples, that vimentin was not detected in non-tumorous cholangiocytes (0/22) but was expressed 
in the tumor cells of most (16/23) ICC samples included in the tissue microarray. On the other hand, 
only 2/17 hilar CCA and 1/18 HCC showed positive staining for vimentin in tumor cells. The 
specificity of vimentin expression in ICC was established by statistical analysis using Fisher's test 
(see Figure 5).  
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Discussion 
To our knowledge, this is the first study to investigate the proteome alterations that occur in ICC 
while taking account of the important cellular heterogeneity of this tumor. Our strategy combining 
LM to select cholangiocytes, and an AMT tag proteomics methodology appropriate for the analysis 
of small cellular samples, was devised to overcome this challenge.  And indeed, this strategy 
provided strong evidence of specific alterations to glycolysis and organization of the cytoskeleton, 
two protein networks involved in carcinogenesis.  
ICC is a devastating cancer with an incidence increasing worldwide. For this reason, studies have 
been carried out in recent years to clarify the mechanisms underlying the development of this 
cancer, with the aim of developing novel therapeutic strategies. These investigations provided 
evidences that ICC was associated with genetic alterations (38-40) and impaired protein expression 
that could contribute to the proliferation of tumorous cholangiocytes (41, 42). Until now, global 
genome and proteome alterations in ICC have been the subject of little investigation. In particular, 
proteome impairments in ICC had only been explored during one study using liver homogenates 
(43). Indeed, the accurate determination of proteome alterations in ICC is a particularly challenging 
task, because in most tumors, cholangiocytes are embedded in an abundant stroma that may mask 
cholangiocyte signals. Therefore, in order to obtain accurate insights into proteome alterations in 
ICC, we used LM to selectively extract cholangiocytes from liver specimens. 
Another important prerequisite to this study was the choice of a proteomics technique appropriate 
for the analysis of small samples. An AMT tag strategy was adopted because this method had been 
shown to significantly improve proteome coverage for samples originating from microdissected 
breast carcinoma cells (22). In order to exploit each specimen to the maximum, we used 
microdissected cholangiocytes both for the generation of the AMT tag database and the quantitative 
study. The resulting AMT database contained 2,499 distinct peptides belonging to 574 proteins, 460 
of these being characterized by at least two peptides. 
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The first step in quantitative data processing consisted in assessing data quality using two 
independent methods: Chaorder and pairwise correlations. As can be seen from the Chaorder plot 
(Figure 2A), and the pairwise correlation matrix (Figure 2B), acquisitions corresponding to the 
same patient displayed less dispersion, respectively better correlations, than analyses of unrelated 
samples, even though the run order was randomized. Moreover, acquisitions corresponding to the 
controls tended to display better homogeneity than those of cancer patients. The Chaorder plot and 
the correlations between replicates thus confirmed that our data were consistent with samples 
classification and that no outlier run was present. 
We then proceeded to extract the list of peptides that were differentially abundant between the two 
populations using an abundance index (AbI) methodology. The observed AbI distribution was 
skewed toward positive values (see Figure 3A), suggesting that the abundance of peptides in 
tumorous samples was slightly higher than in the control samples. Taking account of this 
observation, we therefore considered the median AbI value (0.140) as the reference point at which 
there was no difference between cancer and control samples. Statistical processing and the 
subsequent filtering of proteins for which no proteotypic peptides were found to be deregulated led 
to a list of 23 proteins with decreased abundance in ICC and 16 proteins exhibiting higher 
abundance in tumor cells (see Table 2). We believe that the rigorous criteria chosen to perform this 
proteomic study warrant a high level of confidence in the final list of deregulated proteins. Indeed, 
using alternative methods (Western-blot and immunohistochemistry), the altered expression of 
some of them (vimentin, profilin 1 and CAII ) could be confirmed in tumorous cholangiocytes (see 
Figure 4). 
Many of the altered proteins in tumorous cholangiocytes were involved in glycolysis and regulation 
of the cytoskeleton. As previously observed in kidney and pancreatic cancers (44, 45), we detected 
an increased abundance of proteins from the glycolytic pathway in ICC. In addition to M2-PK, we 
were able to identify fructose bisphosphate aldolase A and lacticodehydrogenase A. These findings 
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indicate, as suggested many years ago by Otto Warburg (46) for other tumor cells, that glycolysis 
could also be altered in tumorous cholangiocytes. It has recently been shown that aerobic 
glycolysis, a distinctive feature of tumor cells, requires the overexpression of M2-PK, and provides 
a selective growth advantage for these cells (47). We therefore hypothesize that an overabundance 
of this isoform may participate in the development of ICC.  
We also noted an altered protein network involved in cytoskeleton organization and cell motility. In 
particular, we noticed a striking increase in the abundance of vimentin, an intermediate filament 
protein. This protein, expressed in a number carcinomas, has been shown to correlate with the 
invasiveness and poor prognosis of these tumors (48-52). We also demonstrated the impaired 
expression of a group of proteins implicated in the equilibrium between globular and filamentous 
actin. This process, altered during cell transformation (53, 54), is involved in cell motility, which is 
notably increased during invasion and metastasis (55, 56). We found an increase in the abundance 
of actin-binding proteins (Cofilin1, Profilin1, Transgelin2). Cofilin1 had been reported as being 
over-expressed in gastrointestinal endocrine tumors, and the aggressiveness of these tumors had 
been linked with the expression of this protein (57). As for Profilin1 and transgelin2, a contrasting 
expression pattern had been reported in breast and colon cancers (58, 59). The functional 
significance of these differences needs to be clarified, particularly since these proteins had been 
described as tumor suppressors (60, 61). 
We also observed an over-abundance in ICC of S100A11 (Calgizzarin), a protein involved in the 
Ca++ signaling network and in the regulation of cell growth and motility (62, 63). Such alterations 
had also been reported in pancreatic (64) and colon cancers, where disease progression correlated 
with the abundance of this protein in tumor tissues.(65, 66). 
On the other hand, annexins exhibited lower abundance in our ICC samples compared to the 
controls. Increased expression of annexins had been reported in different types of carcinoma, e.g. 
colorectal, bladder, pancreatic, hepatocellular and renal carcinomas (67-71). However, a reduced 
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expression of annexin A2, also observed in head and neck squamous cell and prostate carcinomas 
(72, 73) and osteosarcoma (74), had been linked to the aggressive behavior and metastatic potential 
of these tumors. 
Similarly, as reported in renal carcinoma (75), we observed that the catalytic subunit alpha 1 of 
Na/K ATPase was under-represented in ICC samples. Na/K ATPase had been reported as regulating 
carcinoma cell motility (76) and had been shown to be involved in tight junction formation during 
the biogenesis of polarized cells (77). It has thus been speculated (75) that reduced Na/K ATPase 
activity might be implicated in the loss of cell-cell adhesion. 
Cancer cells attain the migratory and invasive capacities required for metastasis by undergoing a 
phenotypic conversion referred to as the Epithelial to Mesenchymal Transition (EMT) (78). The 
expression of TGFbeta, a potent inducer of EMT (79) is increased in many human cancers (80) 
including ICC (81, 82). Interestingly, the protein alterations found in tumorous cholangiocytes 
(present study) displayed striking similarities with those reported in A549 human lung 
adenocarcinoma cell line (83) during TGFbeta-induced EMT. Specifically, similar impairments of 
vimentin, M2-PK, cofilin1, transgelin 2, Na/K ATPase and S100A11 expression were observed in 
both cases, suggesting that the protein profile of tumorous cholangiocytes fits with that of epithelial 
cells displaying a transition to the mesenchymal phenotype. 
Vimentin is a mesenchymal marker that had been reported to be over-expressed in a number of 
cancers, its expression being associated with EMT (78). During the present study, were able to 
confirm  using tissue microarrays that the over-expression of vimentin was a typical feature of ICC 
because 16 out of 23 (~70%) of the tumors studied expressed this protein. Further experiments will 
be necessary to correlate this finding with EMT. If confirmed, however, this hypothesis might 
provide a basis for the serious outcome of this cancer. It is worth noting that all invasive papillary 
tumors included in the TMA were negative for vimentin (see supplementary table 2 and 
supplementary figure 4), suggesting that these tumors could represent a subtype of ICC. Studies on 
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a larger patient population (with trabecular and papillary cases) are underway to assess the 
generality of these findings. Interestingly, an increased abundance of vimentin was not found in all 
types of CCA: it was only detected in two out of the 17 tumors analyzed from patients with hilar 
CCA. As previously shown by Guedj et al. (84), this tends to confirm that hilar CCA and ICC are 
distinct entities displaying specific protein abundance profiles. Similarly, vimentin expression was 
not found to be a common feature in HCC: it was only expressed in one out of the 18 tumor tissue 
samples analyzed. Overall, these findings suggest, as reported in others cancers (44-48), that 
vimentin could play a role in aggressiveness of ICC and provide a basis for the serious outcome of 
this cancer. 
Conclusion 
Until now, owing to the important cellular heterogeneity of ICC, the specific protein profile of these 
tumors could not be adequately determined. In the present study, we selected an appropriate 
strategy based on LM and AMT tag proteomics, in order to access specific cellular populations and 
analyze their proteome with high sensitivity. We were thus able to describe a panel of 39 proteins 
showing altered abundance profiles in tumorous vs. healthy cholangiocytes. Most of the proteins 
displaying perturbed abundances had not yet been described in the setting of ICC. Interestingly, a 
majority of deregulated proteins were involved in glycolysis and cytoskeleton plasticity/cell 
motility, pathways that had been reported to be implicated in carcinogenesis. While further 
experiments are required to characterize the consequences of these deregulations, we anticipate that 
these data may open the way to novel therapeutic targets or diagnostic tools. In particular, achieving 
a specific diagnosis of ICC among other primary liver cancers is often problematic. Results from 
our tissue microarray experiment suggest that vimentin, in combination with other markers, might 
prove useful as an indicator of particular subtypes of ICC. This will be the subject of a follow-up 
study on a larger number of patients with ICC, hilar CCAand HCC. 
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Figures captions: 
Figure 1: Study design:  Cholangiocytes microdissected from control livers (TB to TF) and from 
intrahepatic cholangiocarcinomas (CA to CD) were pooled prior to sample fractionation and LC-
MS/MS analysis to generate an AMT tag database (A). Individual samples were subsequently 
analyzed by LC-FTMS to determine differential alterations of their proteome (B). 
Figure 2: Quantitative LC-FTMS data quality control. (A) Chaorder plot for the 27 acquisitions (3 
for each sample) color coded by sample. (B) Pairwise correlation matrix of peptide abundances 
measured in each acquisition sorted by sample. 
Figure 3: Distributions of abundance indexes (AbI) for the 1121 peptides detected in both 
populations for the original data (A) and for the permuted data (B). The permutation allowed an 
estimation of the variance of the AbI measure under the assumption that all samples were 
equivalent. The dashed lines in panel A delimit the 95% confidence interval (-0.24<AbI<0.53), 
equal to the median AbI (0,14) of the original data plus or minus 1.96 times the standard deviation 
(0,199) of the permuted data; region where no change in abundance between the two populations 
was observed. 
Figure 4: Expression analysis of Vimentin, Carbonic anhydrase 2 (CAII) and Profilin-1 in  
intrahepatic cholangiocarcinoma. (A) Cell plot of log of peptides abundances in cancer and control 
samples. Outline colors correspond to: peptides returned as significant by the statistical analysis 
(blue), peptides shared with other protein groups (pink), peptides not returned as significant by the 
statistical analysis (yellow) and population-specific peptides (grey). (B) Immunodetection of 
Vimentin, CAII and profilin-1. Western blots carried out as described in Material and Methods, 
were performed using microdissected tumorous and non-tumorous cholangiocytes from subjects 
included in the study. (C) Immunohistochemical analysis of vimentin and CAII. 
Immunohistochemistry was performed as described in Experimental procedures. Data from a 
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representative experiment including the tumorous and non tumorous areas of the liver of the patient 
CA and a control liver TB. Vimentin is expressed in tumorous cholangiocytes from ICC (a) and 
negative in non-tumorous cholangiocytes of peripheral (b) and perihilar (c) bile ducts. Internal 
controls as vascular smooth muscle cells and inflammatory cells are positive. Conversely, CAII is 
negative in tumorous cholangiocytes from ICC (d) and expressed in non-tumorous cholangiocytes 
of peripheral (e) and perihilar (f) bile ducts. 
Figure 5: Vimentin expression in liver lesions by immunohistochemical staining using Tissue-
microArray. (A) Representative cores of perihilar bile duct (1), intrahepatic cholangiocarcinoma 
(2), hilar cholangiocarcinoma (3) and hepatocellular carcinoma (4) .IHC staining was performed as 
described in Experimental Procedures. Vimentin is negative in normal cholangiocytes from 
perihilar bile duct whereas inflammatory cells stained as positive internal controls (1). Vimentin is 
diffusely positive in the tumorous cholangiocytes from ICC (2) and totally negative in the tumorous 
cholangiocytes from hilar cholangiocarcinoma (3) and tumorous hepatocytes from HCC (4) (B) 
Vimentin expression in 23 intrahepatic cholangiocarcinoma, 17 hilar cholangiocarcinoma, 18 
hepatocellular carcinoma and 22 controls patients (7 perihilar areas from liver without ICC, 4 
normal livers from amyloid neuropathy and 11 non-tumoral counterparts of ICC). Staining was 
considered as negative when less than 5% of the cells of interest were immunostained. a) * p < 
0.001 (Two-tailed Fisher’s exact text)  
Tables captions: 
Table 1: Clinicopathological characteristics of patients used in MS study. All ICC samples (CA to 
CD) were CK7 positive and CK20 negative. Before surgery, patients did not receive any treatment. 
Perihilar areas from non-biliary pathology (TB to TF) were used as control samples. 
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Table 2: Identification of deregulated proteins in tumorous cholangiocytes. List of proteins 
identified with at least two proteotypic peptides and at least one of them detected with AbI > 0.53 or 
AbI <-0.24. 
Supporting information 
Supplementary Table 1: Database search parameters used for peptides identification. 
Supplementary Table 2: Clinicopathologic features and vimentin expression of patients included in 
the tissue microarray. ). Positive (+)  or negative (-)  staining only concern cholangiocytes staining 
in control liver samples, ICC and hilar cholangiocarcinoma and hepatocytes in HCC. 
Supplementary Table 3: Protein groups identified in the AMT database and corresponding protein 
accessions. 
Supplementary Table 4: datasets resulting from the averaging of replicate analyses for the 4 cancer 
patients and the 5 controls. 
Supplementary Table 5: Proteins covered exlusively by population specific peptides. 
Supplementary Table 6: List of all peptides in the AMT tag database, their sequence, molecular 
weight, modifications when applicable, the corresponding protein groups, and information on 
proteotypicity. 
Supplementary Figure 1: Microdissection of tumorous cholangiocytes. H&E stained liver sections 
before (A and B) and after (C) the laser microdissection of cholangiocytes. 
Supplementary Figure 2: Individual tandem mass spectra for single hits proteins. 
Supplementary Figure 3: Subcellular location of proteins of AMT tag database using Ingenuity 
Pathway Analysis. 
Supplementary Figure 4:  Analysis of Vimentin expression by IHC of the 4 invasive papillary 
cholangiocarcinomas included in TMA. a, b, c and d correspond to case 1, 2, 3 and 4 respectively 
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Table 1: Clinical data of the subjects included in the mass spectrometry analysis.
ID Gender Age Liver lesion Tumor size Histological type
CA F 39 Intrahepatic cholangiocarcinoma 7cm Glandular structure
CB F 62 Intrahepatic cholangiocarcinoma 6cm Mixed architecture
CC M 77 Intrahepatic cholangiocarcinoma 12cm Glandular structure
CD M 55 Intrahepatic cholangiocarcinoma 14cm Compact architecture
TB M 48 Cirrhosis - -
TC M 53 Cirrhosis - -
TD F 45 Sub-acute hepatitis - -
TE F 61 Cirrhosis - -
TF M 53 Hepatocellular carcinoma - -
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Table 2: Identification of deregulated proteins in tumorous cholangiocytes
Accession 
number Protein Name
Gene 
name
Fold change 
Cancer / 
Normal
Sequence 
coverage
Unique peptides / 
proteotypic 
peptides
Protein 
Score Postulated Biological process
a
Proteins having peptides detected with increased abundance in tumorous samples
VIME_HUMAN Vimentin VIM 9.26 68.5% 39/34 2496 cell motion
LDHB_HUMAN L-lactate dehydrogenase B chain LDHB 7.72 37.4% 11/10 808 monocarboxylic acid metabolic process
Q5JP53_HUMAN Tubulin beta polypeptide TUBB 4.76 33.8% 16/3 1098 cell motion
Q1WM23_HUMAN Nucleoside diphosphate kinase NME1 3.66 32.6% 8/8 431 regulation of cell proliferation, metastatic process
LDHA_HUMAN L-lactate dehydrogenase A chain LDHA 3.45 34.0% 10/9 620 anaerobic glycolysis
S10AB_HUMAN Protein S100-A11 (Calgizzarin) S100A11 3.01 43.8% 5/5 293 signal transduction, regulation of cell proliferation
ALDOA_HUMAN Fructose-bisphosphate aldolase A ALDOA 2.28 31.0% 10/10 531 actin cytoskeleton organization, hexose metabolic process
KPYM_HUMAN Pyruvate kinase M2 PKM2 2.17 45.2% 20/20 1410 hexose metabolic process
A8K220_HUMAN Peptidyl-prolyl cis-trans isomerase (Cyclophilin) PPIA 2.16 50.3% 11/11 811 protein folding
K1C18_HUMAN Keratin, type I cytoskeletal 18 KRT18 2.12 64.9% 33/32 2571 cell morphogenesis
PROF1_HUMAN Profilin-1 PFN1 1.97 55.0% 8/8 457 actin cytoskeleton organization
Q6FGI1_HUMAN Transgelin-2 TAGLN2 1.86 33.2% 6/6 355 actin cytoskeleton regulation
PTMA_HUMAN Prothymosin alpha PTMA 1.86 21.6% 2/2 126 transcription
COF1_HUMAN Cofilin-1 CFL1 1.70 50.0% 6/6 433 actin cytoskeleton organization
MDHC_HUMAN Malate dehydrogenase, cytoplasmic MDH1 1.68 29.9% 8/8 517 carboxylic acid metabolic process
HS90B_HUMAN Heat shock protein HSP 90-beta HSP90AB1 1.47 15.5% 11/5 739 molecular chaperone, protein folding
Proteins having peptides detected with decreased abundance in tumorous samples
AGR2_HUMAN Anterior gradient protein 2 AGR2 0.09 22.3% 4/4 208 unknown
CAH2_HUMAN Carbonic anhydrase 2 CA2 0.09 25.4% 6/6 353 response to osmotic stress
ANX13_HUMAN Annexin A13 ANXA13 0.23 33.9% 9/9 480 cell differentiation
A8K008_HUMAN cDNA FLJ78387 - 0.26 11.2% 4/4 237 unknown
A0A5C9_HUMAN IGLV2-14 protein IGLV2-14 0.31 12.4% 2/2 107 unknown
K1C19_HUMAN Keratin, type I cytoskeletal 19 KRT19 0.32 59.3% 32/21 2330 actin cytoskeleton organization
EST1_HUMAN Liver carboxylesterase 1 CES1 0.32 34.0% 16/16 1091 metabolic process
LEG4_HUMAN Galectin-4 LGALS4 0.35 12.7% 3/3 187 cell adhesion
HBA_HUMAN Hemoglobin subunit alpha HBA1 0.39 39.4% 6/6 328 oxygen transport
Q06AH7_HUMAN Transferrin TF 0.45 5.7% 4/4 172 iron ion transport
AT1A1_HUMAN Sodium/potassium-transporting ATPase subunit alpha-1 ATP1A1 0.49 25.1% 19/19 1244 cellular ion homeostasis, carcinoma cell motility
ANXA4_HUMAN Annexin A4 ANXA4 0.49 56.4% 23/23 1885 signal transduction, anti-apoptosis
ERLN2_HUMAN Erlin-2 ERLIN2 0.50 10.6% 3/3 180 unknown
ALBU_HUMAN Serum albumin ALB 0.51 56.5% 39/39 2418 transport
A4GX73_HUMAN Hemoglobin subunit beta HBB 0.51 75.5% 9/4 678 oxygen transport
A4D1PA_HUMAN Aldo-keto reductase family 1, member B10 AKR1B10 0.55 13.6% 4/4 271 cellular lipid metabolic process
TALDO_HUMAN Transaldolase TALDO1 0.56 14.8% 5/5 213 carbohydrate metabolic process
A0A5E5_HUMAN IGKC Protein IGKC 0.57 24.2% 4/4 304 immune response
AK1C1_HUMAN Aldo-keto reductase family 1 member C1 AKR1C1 0.62 14.6% 3/3 116 steroid metabolic process
HSP71_HUMAN Heat shock 70 kDa protein 1 HSPA1A 0.63 27.5% 15/4 975 ubuquitin proteasome pathway, protein folding
PDIA3_HUMAN Protein disulfide-isomerase A3 PDIA3 0.68 26.3% 11/11 646 protein folding
ANXA2_HUMAN Annexin A2 ANXA2 0.79 53.1% 17/17 1189 actin cytoskeleton organization
A1A5C4_HUMAN RRBP1 protein RRBP1 0.80 10.6% 9/9 427 translation
a) Postulated biological process was determined by Gene Ontology (GO) and bibliographic features
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